Bavarian Nordic reviewing partners for cancer vax

Bavarian Nordic says it has gathered between five and nine term sheets from potential partners for its experimental prostate cancer vaccine. The company's business development chief, Juergen Langhaerig, told a conference that the mix of international companies included some of the "largest companies in the world, the top 10, and some are mid-sized, fast-growing companies." Story

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.